Variant has entered a multi-year research partnership with Novo Nordisk to identify new targets to treat metabolic conditions.

The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.

The FDA has granted ODD to Tempest's amezalpat (TPST-1120), for individuals with hepatocellular carcinoma (HCC).

The landscape of pandemic response has been transformed, with new standards being set for clinical excellence. A new report looks at emerging therapies, trial insights, and the innovations shaping the ...